Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 36


What are the dominant cytokines in early rheumatoid arthritis?

Ridgley LA, Anderson AE, Pratt AG.

Curr Opin Rheumatol. 2017 Dec 4. doi: 10.1097/BOR.0000000000000470. [Epub ahead of print]


CD4+ and B lymphocyte expression quantitative traits at rheumatoid arthritis risk loci in untreated early arthritis: implications for causal gene identification.

Thalayasingam N, Nair N, Skelton AJ, Massey J, Anderson AE, Clark AD, Diboll J, Lendrem DW, Reynard LN, Cordell HJ, Eyre S, Isaacs JD, Barton A, Pratt AG.

Arthritis Rheumatol. 2017 Nov 28. doi: 10.1002/art.40393. [Epub ahead of print]


The interferon gene signature is increased in patients with early treatment-naive rheumatoid arthritis and predicts a poorer response to initial therapy.

Cooles FAH, Anderson AE, Lendrem DW, Norris J, Pratt AG, Hilkens CMU, Isaacs JD.

J Allergy Clin Immunol. 2017 Oct 5. pii: S0091-6749(17)31568-3. doi: 10.1016/j.jaci.2017.08.026. [Epub ahead of print] No abstract available.


Patient and researcher perspectives on facilitating patient and public involvement in rheumatology research.

Pollock J, Raza K, Pratt AG, Hanson H, Siebert S, Filer A, Isaacs JD, Buckley CD, McInnes IB, Falahee M.

Musculoskeletal Care. 2017 Dec;15(4):395-399. doi: 10.1002/msc.1171. Epub 2016 Dec 16. No abstract available.


Let's not fool ourselves. In RA, the ACR/EULAR remission criteria are not perfect!

Baker KF, Pratt AG, Thompson B, Isaacs JD.

Ann Rheum Dis. 2017 Jun;76(6):e12. doi: 10.1136/annrheumdis-2016-210797. Epub 2016 Dec 1. No abstract available.


Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers.

Brown PM, Pratt AG, Isaacs JD.

Nat Rev Rheumatol. 2016 Dec;12(12):731-742. doi: 10.1038/nrrheum.2016.175. Epub 2016 Oct 27. Review.


Tolerogenic dendritic cells generated with dexamethasone and vitamin D3 regulate rheumatoid arthritis CD4+ T cells partly via transforming growth factor-β1.

Anderson AE, Swan DJ, Wong OY, Buck M, Eltherington O, Harry RA, Patterson AM, Pratt AG, Reynolds G, Doran JP, Kirby JA, Isaacs JD, Hilkens CM.

Clin Exp Immunol. 2017 Jan;187(1):113-123. doi: 10.1111/cei.12870. Epub 2016 Nov 2.


Capture Hi-C identifies a novel causal gene, IL20RA, in the pan-autoimmune genetic susceptibility region 6q23.

McGovern A, Schoenfelder S, Martin P, Massey J, Duffus K, Plant D, Yarwood A, Pratt AG, Anderson AE, Isaacs JD, Diboll J, Thalayasingam N, Ospelt C, Barton A, Worthington J, Fraser P, Eyre S, Orozco G.

Genome Biol. 2016 Nov 1;17(1):212.


Components of treatment delay in rheumatoid arthritis differ according to autoantibody status: validation of a single-centre observation using national audit data.

Pratt AG, Lendrem D, Hargreaves B, Aslam O, Galloway JB, Isaacs JD.

Rheumatology (Oxford). 2016 Oct;55(10):1843-8. doi: 10.1093/rheumatology/kew261. Epub 2016 Jul 3.


Bcl-3 in CD4+ T Cell-Mediated Rheumatoid Arthritis Pathogenesis: Comment on the Article by Meguro et al.

Pratt AG, Anderson AE, Carmody RJ, Isaacs JD.

Arthritis Rheumatol. 2016 Mar;68(3):770-1. doi: 10.1002/art.39509. No abstract available.


Synovial CD4+ T-cell-derived GM-CSF supports the differentiation of an inflammatory dendritic cell population in rheumatoid arthritis.

Reynolds G, Gibbon JR, Pratt AG, Wood MJ, Coady D, Raftery G, Lorenzi AR, Gray A, Filer A, Buckley CD, Haniffa MA, Isaacs JD, Hilkens CM.

Ann Rheum Dis. 2016 May;75(5):899-907. doi: 10.1136/annrheumdis-2014-206578. Epub 2015 Apr 28.


IL-6-driven STAT signalling in circulating CD4+ lymphocytes is a marker for early anticitrullinated peptide antibody-negative rheumatoid arthritis.

Anderson AE, Pratt AG, Sedhom MA, Doran JP, Routledge C, Hargreaves B, Brown PM, Lê Cao KA, Isaacs JD, Thomas R.

Ann Rheum Dis. 2016 Feb;75(2):466-73. doi: 10.1136/annrheumdis-2014-205850. Epub 2015 Feb 3.


Genotyping in rheumatoid arthritis: a game changer in clinical management?

Pratt AG, Isaacs JD.

Expert Rev Clin Immunol. 2015 Mar;11(3):303-5. doi: 10.1586/1744666X.2015.1008454. Epub 2015 Feb 2.


Seronegative rheumatoid arthritis: pathogenetic and therapeutic aspects.

Pratt AG, Isaacs JD.

Best Pract Res Clin Rheumatol. 2014 Aug;28(4):651-9. doi: 10.1016/j.berh.2014.10.016. Epub 2014 Nov 18. Review.


Retrospective analysis of the role of serum vitamin D in early rheumatic disease.

Cooles FA, Pratt AG, Lendrem DW, Ng WF, Aspray TJ, Isaacs JD.

Rheumatology (Oxford). 2015 Feb;54(2):374-5. doi: 10.1093/rheumatology/keu420. Epub 2014 Nov 17. No abstract available.


A CD4 T cell gene signature for early rheumatoid arthritis implicates interleukin 6-mediated STAT3 signalling, particularly in anti-citrullinated peptide antibody-negative disease.

Pratt AG, Swan DC, Richardson S, Wilson G, Hilkens CM, Young DA, Isaacs JD.

Ann Rheum Dis. 2012 Aug;71(8):1374-81. doi: 10.1136/annrheumdis-2011-200968. Epub 2012 Apr 24.


Prevalence and diagnostic outcome relating to vitamin D deficiency in new patients presenting to an early arthritis clinic over 12 months.

Cooles FA, Pratt AG, Wilson G, Isaacs JD, Ng WF.

Clin Rheumatol. 2011 Aug;30(8):1137-8. doi: 10.1007/s10067-011-1800-8. Epub 2011 Jun 24. No abstract available.


Serotyping for an extended anti-citrullinated peptide autoantibody panel does not add value to CCP2 testing for diagnosing RA in an early undifferentiated arthritis cohort.

Pratt AG, Charles PJ, Chowdhury M, Wilson G, Venables PJ, Isaacs JD.

Ann Rheum Dis. 2011 Nov;70(11):2056-8. doi: 10.1136/ard.2010.148197. Epub 2011 May 27. No abstract available.


The clinical utility of a rule for predicting rheumatoid arthritis in patients with early undifferentiated arthritis: comment on the article by van der Helm-van Mil et al.

Pratt AG, Isaacs JD, Wilson G.

Arthritis Rheum. 2009 Mar;60(3):905; author reply 906. doi: 10.1002/art.24348. No abstract available.

Supplemental Content

Loading ...
Support Center